Interestingly, since there was no significant survival rate difference in prostate adenocarcinoma (PA) patients who showed high or low ZNF507 expression, considerably higher ZNF507 level was observed in recurrent PC tumors (Fig. 1C, D). Here, ZNF507 is linked to pachyonychia congenita.